EPIDERMOID URETHRAL CARCINOMA: A CASE REPORT

• Autor(a) principal: Bezerra, Mariana Cunha Paes
• Data de Publicação: 2024
• Outros Autores: Albuquerque , Marina Acioly Cavalcanti de, Revoredo , Luiza Maciel Yamamoto, Revorêdo , Laís Maciel Yamamoto, Albuquerque , Mariana Acioly Cavalcanti de, Barros , Felipe Dubourcq de, Júnior , Francisco de Morais Lima
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1280
• topic: Câncer de Colo do Útero; Mortalidade; Epidemiologia; Declaração de Óbito; Sistema de Informação de Mortalidade; HPV; Neoplasia Maligna Genital Feminina.; Uterine Cervical Neoplasms, prevention and control; Prevention of uterine cell neoplasms; Pap smear; Health services coverage; Massive crib

Introduction: epidermoid urethral carcinoma, also called squamous cell or squamous cell carcinoma, is a rare neoplasm, it has a higher incidence in advanced ages and in males. Risk factors are strongly related to sexually transmitted infections, especially HPV, and recurrent urinary tract infections. Because it is a disease of difficult recognition in clinical practice, the diagnosis is made in advanced stages, often with the presence of  metastases, lead to a worse prognosis. Objectives:     to  report the case of a  patient with epidermoid urethral carcinoma. Methodology:  it is a descriptive case report type study which data collection took place at the Hospital de Câncer de Pernambuco in Recife-PE. The study population is 01 patitent with  epidermoid urethral neoplasm. Discussion: squamous cell carcinoma originates in the epithelium covering and its etiopathogenesis is associated with poor hygiene conditions and viral infections. The treatment of choice is a controversial issue in the  literature, but the one that allows the greatest remission of the disease should be chosen, as in most cases, in the case described, tumor resection surgery was chosen, associated with adjuvant chemotherapy with cisplatin and paclitaxel, allowing the remission of metastatic disease and recovery your activities until the last contact, in December 2021. Conclusion: Because it is uncommon, it has divergences regarding its incidence, prevalence and better treatment to be instituted. Since the survival decreases over the years, it is important to perform adequate follow up to monitor the return or progress of the disease.